A phase 2 study of Rituximab‐Bendamustine and Rituximab‐Cytarabine for transplant‐eligible patients with mantle cell lymphoma
Philippe Armand(Harvard University), Eric D. Jacobsen(Dana-Farber Cancer Institute), Jennifer R. Brown(Dana-Farber Cancer Institute), Li Weng, Angela Giardino(Dana-Farber Cancer Institute), Robin Joyce(Beth Israel Deaconess Medical Center), Caron A. Jacobson(Dana-Farber Cancer Institute), Arnold S. Freedman(Otsuka (Japan)), Sangeetha Mayuram(Dana-Farber Cancer Institute), Jennifer Wilkins, Matthew S. Davids(Dana-Farber Cancer Institute), Ann S. LaCasce(Otsuka (Japan)), David C. Fisher(Dana-Farber Cancer Institute), Jad Bsat(Dana-Farber Cancer Institute), Malek Faham, Robert Redd(Harvard University)
Cited by 68
Related Papers
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
|New England Journal of Medicine|2014|3.5k
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k